Ghent, Belgium, 22th February 2011 – Pronota NV today announced that it has entered into an agreement with Molecuence Corporation, a wholly owned subsidiary of Mitsubishi Chemical Corporation, to discover and validate protein biomarkers in stroke. Pronota will apply its proven proprietary platforms for protein biomarker discovery (MASStermind®) and biomarker verification MASSterclass™) to this project. The financial terms have not been disclosed.
“We’re finding potential collaborators are increasingly persuaded by our track record of not only being able to identify novel protein biomarkers, but also of taking these successfully through the verification process to show they are true, robust and clinically relevant discoveries. We’re delighted to be working with Molecuence, who are one of the leaders in the field of protein biomarker development for diagnostic applications”, commented Nick McCooke, CEO of Pronota.
Pronota was founded in late 2004 to develop protein biomarker diagnostics derived from its proprietary platform that uniquely mines for low-abundance protein biomarkers in blood and other tissues. In this short time, it has successfully implemented its technology and made substantial progress in creating a diagnostic product development pipeline.
Its MASStermind® protein biomarker discovery platform has demonstrated, across many projects, its unerring ability to discover clinically relevant and novel protein biomarkers. Its MASSterclass™ verification platform provides it with a way of verifying within a matter of weeks the prolific output from MASStermind without having to resort to the use of antibody based assays.
Molecuence Corporation is a wholly owned subsidiary of Mitsubishi Chemical Corporation. The company is principally involved in the development of disease related biomarkers that can enable diagnosis and prediction of accurate disease status. Currently, the company is involved in research and development of advanced biomarkers for cardiovascular and metabolic diseases. Molecuence works in partnership with Kyushu university faculty of medicine and Hisayama research institute for lifestyle diseases. The company is headquartered in Yokohama, Japan.